Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0028754 (
obesity
)
124,988
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Obesity
is an alarming primary health problem and is an independent risk factor for type II diabetes, cardiovascular diseases, and hypertension. Although the pathologic mechanisms linking
obesity
with these co-morbidities are most likely multifactorial, increasing evidence indicates that altered secretion of adipose-derived signaling molecules (adipokines; e.g. adiponectin, leptin, and tumor necrosis factor alpha) and local inflammatory responses are contributing factors. Chemerin (RARRES2 or TIG2) is a recently discovered chemoattractant protein that serves as a ligand for the G protein-coupled receptor CMKLR1 (ChemR23 or DEZ) and has a role in adaptive and innate immunity. Here we show an unexpected, high level expression of
chemerin
and its cognate receptor CMKLR1 in mouse and human adipocytes. Cultured 3T3-L1 adipocytes secrete
chemerin
protein, which triggers CMKLR1 signaling in adipocytes and other cell types and stimulates chemotaxis of CMKLR1-expressing cells. Adenoviral small hairpin RNA targeted knockdown of
chemerin
or CMKLR1 expression impairs differentiation of 3T3-L1 cells into adipocytes, reduces the expression of adipocyte genes involved in glucose and lipid homeostasis, and alters metabolic functions in mature adipocytes. We conclude that
chemerin
is a novel adipose-derived signaling molecule that regulates adipogenesis and adipocyte metabolism.
...
PMID:Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. 1763 25
Soluble protein hormones are key regulators of a number of metabolic processes, including food intake and insulin sensitivity. We have used a signal sequence trap to identify genes that encode secreted or membrane-bound proteins in Psammomys obesus, an animal model of
obesity
and type 2 diabetes (T2D). Using this signal sequence trap, we identified the chemokine
chemerin
as being a novel adipokine. Gene expression of
chemerin
and its receptor, chemokine-like receptor 1 (CMKLR1), was significantly higher in adipose tissue of obese and type 2 diabetic P. obesus compared with lean, normoglycemic P. obesus. Fractionation of P. obesus adipose tissue confirmed that
chemerin
was predominantly expressed in adipocytes, whereas CMKLR1 was expressed in both adipocytes and stromal-vascular cells of adipose tissue. In 3T3-L1 adipocytes,
chemerin
was markedly induced during differentiation, whereas CMKLR1 was down-regulated during differentiation. Serum
chemerin
levels were measured by ELISA in human plasma samples from 114 subjects with T2D and 142 normal glucose tolerant controls. Plasma
chemerin
levels were not significantly different between subjects with T2D and normal controls. However, in normal glucose tolerant subjects, plasma
chemerin
levels were significantly associated with body mass index, circulating triglycerides, and blood pressure. Here we report, for the first time, that
chemerin
is an adipokine, and circulating levels of
chemerin
are associated with several key aspects of metabolic syndrome.
...
PMID:Chemerin is a novel adipokine associated with obesity and metabolic syndrome. 1764 Sep 97
Interest in the biology of white adipose tissue has increased dramatically since the discovery of leptin in 1994. The identification of the product of the gene obese (ob) threw light on the role of adipose tissue in the physiopathology of
obesity
-related diseases and spurred the identification of numerous other adipokines, many of a proinflammatory nature. It has become increasingly evident that white adipose tissue-derived cytokines mediate between
obesity
-related exogenous factors (nutrition and lifestyle) and the molecular events that lead to metabolic syndrome, inflammation, and cardiovascular diseases. Here we review recent adipokine research, with particular attention to the roles of adiponectin, leptin, resistin, visfatin, apelin, omentin, and
chemerin
in such conditions.
...
PMID:The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. 1802 38
Obesity
is associated with an array of health problems in adult and pediatric populations. Understanding the pathogenesis of
obesity
and its metabolic sequelae has advanced rapidly over the past decades. Adipose tissue represents an active endocrine organ that, in addition to regulating fat mass and nutrient homeostasis, releases a large number of bioactive mediators (adipokines) that signal to organs of metabolic importance including brain, liver, skeletal muscle, and the immune system--thereby modulating hemostasis, blood pressure, lipid and glucose metabolism, inflammation, and atherosclerosis. In the present review, we summarize current data on the effect of the adipose tissue-derived hormones adiponectin,
chemerin
, leptin, omentin, resistin, retinol binding protein 4, tumor necrosis factor-alpha and interleukin-6, vaspin, and visfatin on insulin resistance.
...
PMID:Adipokines and insulin resistance. 1900 16
Fat is either white or brown, the latter being found principally in neonates. White fat, which comprises adipocytes, pre-adipocytes, macrophages, endothelial cells, fibroblasts, and leukocytes, actively participates in hormonal and inflammatory systems. Adipokines include hormones such as leptin, adiponectin, visfatin, apelin, vaspin, hepcidine,
chemerin
, omentin, and inflammatory cytokines, including tumor necrosis factor alpha (TNF), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator protein (PAI). Multiple roles in metabolic and inflammatory responses have been assigned to adipokines; this review describes the molecular actions and clinical significance of the more important adipokines. The array of adipokines evidences diverse roles for adipose tissue, which looms large in the mediators of inflammation and metabolism. For this reason, treating
obesity
is more than a reduction of excess fat; it is also the treatment of
obesity
's comorbidities, many of which will some day be treated by drugs that counteract derangements induced by adipokine excesses.
...
PMID:Adipose tissue: the new endocrine organ? A review article. 1905 66
Adipose tissue cells express and secrete numerous proteins influencing the signal transduction pathways of insulin receptor by auto-, para- and endocrine manner. Several cytokines, tumor necrosis factor-alpha and its soluble receptor forms, sTNFR1 and sTNFR2, resistin, retinol-binding protein 4, plasminogen activator inhibitor, lipocain 1 inhibit the signalization of insulin receptor causing insulin resistance in target tissues, mainly in adipose, liver and muscle, brain, endothelial as well as in pancreatic beta-cells. However, many other proteins produced by the fat tissue, such as adiponectin, visfatin, vaspin, apelin, omentin and
chemerin
enhance the signal transmission of the receptor. Recently discovered common mechanisms leading to insulin and cytokine resistance in
obesity
and type 2 diabetes mellitus, e.g. protein family of suppressor of cytokine signaling (SOCS) are also discussed.
...
PMID:[Molecular mechanisms and correlations of insulin resistance, obesity, and type 2 diabetes mellitus]. 1972 6
White adipose tissue has traditionally been regarded as an organ of energy storage and mobilization. However, it is now recognized that this tissue is also an active endocrine organ that secretes a variety of signaling molecules termed adipokines. These adipokines have diverse autocrine-, paracrine-, and endocrine-like actions that impact a variety of biological and physiological processes, including adipocyte differentiation, local and systemic inflammation, overall energy balance, blood pressure, and glucose and lipid metabolism. Given the regulatory influence on these critical functions, dysregulation of adipokine secretion is believed to be a major contributor to
obesity
-related disorders such as hypertension, diabetes, and cardiovascular disease. Chemerin is a small, secreted protein that has been reported to serve as a chemoattractant for cells of the immune system such as macrophages and immature dendritic cells that express the cognate receptor chemokine-like receptor-1 (CMKLR1). Using adenoviral- delivered, short hairpin RNAs (shRNAs) to suppress
chemerin
or CMKLR1 expression, we have demonstrated a novel role for
chemerin
/CMKLR1 signaling as a positive regulator of adipocyte differentiation and metabolic function in the 3T3-L1 model of adipogenesis. This experimental approach provides an efficient and powerful means to characterize the functional roles of genes known to be involved in adipocyte formation and metabolism as well as to identify novel roles for genes in this model and/or other cells.
...
PMID:Elucidation of chemerin and chemokine-like receptor-1 function in adipocytes by adenoviral-mediated shRNA knockdown of gene expression. 1944 31
Chemerin is a novel peptide that was identified as a natural ligand for ChemR23. As it has been reported to be involved in the regulation of immune responses and adipogenesis,
chemerin
may have a variety of physiological functions. Chemerin is synthesized as a precursor (prochemerin) and is proteolytically activated and inactivated in sequential steps, which control its physiological roles in a coordinated manner. Chemerin-9 (chemerin148-156) was previously identified as the smallest peptide with low nanomolar potency. However, like mature
chemerin
,
chemerin
-9 is rapidly degraded and inactivated in plasma, which has limited the use of
chemerin
-9 in in vivo experiments. In order to identify stable
chemerin
analogs that facilitate in vivo studies, we synthesized a series of
chemerin
-9 analogs and examined intrinsic activity and metabolic stability. We identified an agonistic and metabolically stable
chemerin
-9 analog (d-Tyr(147)-[d-Ser(151), d-Ala(154), Tic(155)]chemerin148-156) that shows enhanced plasma exposure with prolonged half-life in mice upon intraperitoneal administration. Improvement of metabolic stability resulted in a reduction in the plasma free fatty acid levels in fasted mice, which cannot be accomplished by unstable-mouse
chemerin
-9. This reduction in plasma free fatty acids reflects the anti-lipolysis activity of
chemerin
-9 and analogs in mouse primary adipocytes. The discovery of a metabolically stable
chemerin
analog will facilitate investigation of the pharmacological roles of
chemerin
in vivo. Moreover, this stable
chemerin
analog might provide new therapeutic approaches to inflammatory diseases such as asthma and metabolic disorders such as
obesity
and diabetes where ChemR23 activation may be of benefit.
...
PMID:Identification of a stable chemerin analog with potent activity toward ChemR23. 1954 Feb 90
White adipose tissue (WAT) stores energy in the form of triglycerides, whereas brown tissue (BAT) expends energy, primarily by oxidizing lipids. WAT also secretes many cytokines and acute-phase proteins that contribute to insulin resistance in obese subjects. In this study, we have investigated the mechanisms by which activation of peroxisome proliferator-activated receptor gamma (PPARgamma) with synthetic agonists induces a brown phenotype in white adipocytes in vivo and in vitro. We demonstrate that this phenotypic conversion is characterized by repression of a set of white fat genes ("visceral white"), including the resistin, angiotensinogen, and
chemerin
genes, in addition to induction of brown-specific genes, such as Ucp-1. Importantly, the level of expression of the "visceral white" genes is high in mesenteric and gonadal WAT depots but low in the subcutaneous WAT depot and in BAT. Mutation of critical amino acids within helix 7 of the ligand-binding domain of PPARgamma prevents inhibition of visceral white gene expression by the synthetic agonists and therefore shows a direct role for PPARgamma in the repression process. Inhibition of the white adipocyte genes also depends on the expression of C/EBPalpha and the corepressors, carboxy-terminal binding proteins 1 and 2 (CtBP1/2). The data further show that repression of resistin and angiotensinogen expression involves recruitment of CtBP1/2, directed by C/EBPalpha, to the minimal promoter of the corresponding genes in response to the PPARgamma ligand. Developing strategies to enhance the brown phenotype in white adipocytes while reducing secretion of stress-related cytokines from visceral WAT is a means to combat
obesity
-associated disorders.
...
PMID:C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. 1956 8
A strong causal link between increased adipose tissue mass and insulin resistance in tissues such as liver and skeletal muscle exists in
obesity
-related disorders such as type 2 diabetes. Increased adipose tissue mass in obese patients and patients with diabetes is associated with altered secretion of adipokines, which also includes chemotactic proteins. Adipose tissue releases a wide range of chemotactic proteins including many chemokines and
chemerin
, which are interesting targets for adipose tissue biology and for biomedical research in
obesity
and
obesity
-related diseases. This class of adipokines may be directly linked to a chronic state of low-grade inflammation and macrophage infiltration in adipose tissue, a concept intensively studied in adipose tissue biology in recent years. The inflammatory state of adipose tissue in obese patients may be the most important factor linking increased adipose tissue mass to insulin resistance. Furthermore, chemoattractant adipokines may play an important role in this situation, as many of these proteins possess biological activity beyond the recruitment of immune cells including effects on adipogenesis and glucose homeostasis in insulin-sensitive tissues. The present review provides a summary of experimental evidence of the role of adipose tissue-derived chemotactic cytokines and their function in insulin resistance in vivo and in vitro.
...
PMID:Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? 1969 4
1
2
3
4
5
6
7
8
9
10
Next >>